Welcome to our dedicated page for Neogen news (Ticker: NEOG), a resource for investors and traders seeking the latest updates and insights on Neogen stock.
Neogen Corporation (NASDAQ: NEOG) generates a steady flow of news related to food safety, animal safety, and global food security. As a Lansing, Michigan-based manufacturer of diagnostics and related products, Neogen regularly issues updates on its financial performance, segment trends, and strategic actions that affect the Food Safety and Animal Safety markets.
On this page, readers can follow earnings releases where Neogen reports revenue, segment performance, gross margin, and non-GAAP measures such as adjusted EBITDA. These updates often break out results for the Food Safety and Animal Safety segments, discuss core revenue trends versus divestitures and discontinued product lines, and provide commentary on product categories like pathogen detection, indicator testing, culture media, biosecurity, and genomics.
Neogen’s news flow also includes announcements about leadership changes, such as the appointment of a new President and Chief Executive Officer, Chief Financial Officer, and senior commercial and business unit leaders. Board transitions, including director retirements and new director appointments, are disclosed through both press releases and related SEC filings.
Sector-specific items appear in Neogen’s news as well, including collaborations in equine health and vaccine offerings such as BotVax B for botulism Type B in horses. The company also announces participation in investor conferences and the timing of quarterly earnings calls and webcasts.
By reviewing the NEOG news feed on this page, investors and observers can track how Neogen describes its progress in food safety, livestock, and pet health and wellness, as well as its strategic transformation efforts, restructuring actions, and capital allocation decisions over time.
Neogen (NASDAQ: NEOG) announced a voluntary nationwide recall of all lots within expiry of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution packaged as 2mL/20mg and 10mL/50mg vials due to microbial contamination.
The recall cites reports of adverse events in horses after intraarticular use (inconsistent with labeled topical use). Neogen is working with the FDA and arranging product returns; customers should quarantine recalled product and contact AnimalHealth@neogen.com or 859-254-1221.
Neogen (NASDAQ: NEOG) reported Q2 FY2026 revenue of $224.7M (down 2.8% YoY) with core revenue +2.9% YoY. Net loss was $15.9M (loss per diluted share $(0.07)), while Adjusted Net Income was $22.6M and Adjusted EBITDA was $48.7M with an Adjusted EBITDA margin of 21.7%. Gross margin declined to 47.5% from 49.0% due to tariffs, inventory write-offs and mix. Food Safety core growth was positive; Animal Safety revenue declined 11.8% YoY. Cash was $145.3M with $800.0M debt. Company raised FY2026 guidance to $845M–$855M revenue and ~$175M Adjusted EBITDA.
Neogen (NASDAQ: NEOG) announced two senior leadership appointments in January 2026: Joe Freels as Senior Vice President and Chief Commercial Officer, effective January 5, 2026, and Dr. Tammi Ranalli as Senior Vice President and General Manager, Global Food Safety, effective January 7, 2026.
Dr. Ranalli will hold full P&L responsibility for Neogen’s global Food Safety portfolio and lead global strategy across marketing, R&D, and government/regulatory affairs. Freels will lead global Food Safety commercial strategy, including sales, customer and technical services, regional marketing, and commercial excellence. Both executives join from diagnostics and life‑science companies with commercial and operational experience.
Neogen (NASDAQ: NEOG) will release its second-quarter earnings before the market opens on January 8, 2026. Company executives will host a webcast and conference call the same morning at 8:00 a.m. Eastern to discuss results. Access details include toll-free and international phone numbers, a conference ID 82072, and a live webcast on the company investor relations site at investors.neogen.com. A replay will be available shortly after the call via phone and on the investor website.
Neogen (NASDAQ: NEOG) will participate in two investor conferences on January 14, 2026. The company will appear at the CJS Securities 26th Annual New Ideas for the New Year conference (virtual) and at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, where President and CEO Mike Nassif will present at 5:15 PM Pacific on January 14, 2026.
Live webcasts will be available via Neogen’s Investor Relations webpage at investors.neogen.com under “Events & Presentations.”
Neogen (NASDAQ: NEOG) appointed Bryan Riggsbee as Chief Financial Officer effective November 3, 2025. Riggsbee will lead Neogen’s global finance organization and join the Executive Leadership Team, reporting to CEO Mike Nassif. To support a smooth changeover, David Naemura is expected to remain through the end of the calendar year.
Riggsbee brings over 25 years of financial leadership in diagnostics and healthcare, most recently serving as CFO of bioMérieux’s $2 billion North American business and previously as CFO at Myriad Genetics; prior roles include LabCorp, GE, and KPMG. He holds degrees from UNC Chapel Hill, North Carolina State, and an MBA from Kellogg.
Neogen (NASDAQ: NEOG) reported fiscal Q1 2026 results for the quarter ended August 31, 2025: revenue $209.2M, net income $36.3M (EPS $0.17), Adjusted Net Income $9.4M, and Adjusted EBITDA $35.5M (17.0% margin). Gross margin was 45.4% (49.5% ex-integration costs). The company completed the divestiture of its Cleaners & Disinfectants business and used proceeds to repay $100.0M of debt, leaving total debt at $800.0M and cash of $138.9M. Mike Nassif became CEO and President effective August 11, 2025. Company implemented restructuring and headcount reductions and reaffirmed full-year FY2026 guidance of $820M–$840M revenue and $165M–$175M Adjusted EBITDA.
Neogen Corporation (NASDAQ: NEOG) has renewed its sponsorship with the United States Equestrian Federation, extending their partnership that began in April 2024. The collaboration focuses on developing educational materials about equine botulism prevention and treatment for Federation members.
As a key highlight, Neogen manufactures BotVax® B, the only USDA-approved vaccine for Type B botulism in horses. The partnership aims to raise awareness about this deadly neurotoxin that can be found in hay, feed, and soil, threatening equine health.
The renewal demonstrates Neogen's continued commitment to equine health and safety, with both organizations expressing satisfaction with their first year of collaboration and optimism for future developments in equine wellness.
Neogen Corporation (NASDAQ: NEOG) has scheduled its first-quarter earnings release for October 9, 2025, before market open. The company will host a conference call and webcast at 8:00 a.m. Eastern time to discuss the financial results.
Investors can access the conference call via toll-free numbers for North America (1-800-549-8228) and International (+1 646-564-2877) using Conference ID 49915. A replay will be available through the company's Investor Relations website and via phone using passcode 49915.
Neogen Corporation (NASDAQ: NEOG) announced that Chief Financial Officer and Chief Operating Officer David Naemura plans to leave the company. Naemura will continue in his roles until after the company's 10-Q filing in October, with his departure no later than the end of 2025.
The company has initiated a search for a new CFO through a leading executive search firm. During the transition, Bill Waelke, Vice President of Investor Relations & Treasury, will support investor inquiries, while Jim Walter, Vice President of Global Operations, will assume oversight of Global Procurement, reporting to CEO Mike Nassif.